Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with glioblastoma (GBM): Results for cohort B (DUR monotherapy), bevacizumab (BEV) naive patients with recurrent GBM Meeting Abstract
| Authors: | Reardon, D.; Kaley, T.; Dietrich, J.; Lim, M.; Dunn, G.; Gan, H.; Cloughesy, T.; Clarke, J.; Park, A.; Macri, M.; Ryan, A.; Ricciardi, T.; Reddy, V.; Venhaus, R. |
| Abstract Title: | Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with glioblastoma (GBM): Results for cohort B (DUR monotherapy), bevacizumab (BEV) naive patients with recurrent GBM |
| Meeting Title: | 21st Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) |
| Journal Title: | Neuro-Oncology |
| Volume: | 18 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2016 Nov 17-20 |
| Meeting Location: | Scottsdale, AZ |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2016-11-01 |
| Start Page: | vi18 |
| Language: | English |
| ACCESSION: | WOS:000398604101005 |
| PROVIDER: | wos |
| DOI: | 10.1093/neuonc/nox168.108 |
| PMCID: | PMC5692026 |
| Notes: | Meeting Abstract: ATIM-04 -- Source: Wos |
